BRNS holders should prepare for the cessation of trading on September 3, 2026, and the conversion of their shares into the new entity, CLYD. The 0.111 exchange ratio is now fixed. Monitor the court hearing on September 1 for any last-minute complications. Post-merger, the investment thesis shifts to Clywedog Therapeutics (CLYD).
Price Chart
Executive Summary
Barinthus Biotherapeutics (BRNS) is being acquired by Clywedog Therapeutics in an all-stock transaction. The company has notified Nasdaq of its intent to delist its ADSs, with trading expected to halt before the open on September 3, 2026. The Scheme Exchange Ratio has been set at 0.111, and the combined entity (Clywedog Therapeutics Holdings, Inc.) will trade under the ticker CLYD. This filing confirms the final steps of a pre-announced merger, making it a terminal event for BRNS holders.
Key Facts
- Scheme of arrangement expected to become effective on September 3, 2026.
- Trading of BRNS ADSs on Nasdaq expected to halt prior to the opening of trading on September 3, 2026.
- Scheme Exchange Ratio determined at 0.111.
- Company notified Nasdaq of intent to withdraw listing and requested filing of Form 25 to delist and deregister ADSs.
- Following the merger, Topco will be renamed Clywedog Therapeutics Holdings, Inc. and list on Nasdaq under ticker CLYD.
- Court hearing for the scheme of arrangement is scheduled for September 1, 2026.
Financial Impact
BRNS shareholders will receive shares in the new entity (CLYD) at a ratio of 0.111 per BRNS ADS. No cash consideration is involved. The delisting of BRNS is imminent.
Risk Factors
- Risk that the scheme of arrangement or merger does not become effective as planned, though this appears low.
- Risk that the value of the new CLYD shares underperforms expectations post-merger.
- Risk of trading illiquidity in BRNS in the final days before the halt.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-100470 |
| Document: 0001104659-26-100470-index.html | 0001104659-26-100470 |
| Document: 0001104659-26-100470.txt | 0001104659-26-100470 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 6w ago | EFFECT | $0.7400 | awaiting T+20 | — | — |
Aug 25, 2026 9w ago | 8-K | $0.6600 | awaiting T+20 | — | — |
Jul 2, 2026 16w ago | 8-K | $0.6201 $0.5570 | ▲ +10.18% | ▲ +9.76% | — |
May 1, 2026 25w ago | 3 | $0.6350 $0.6810 | ▲ +7.24% | ▲ +1.60% | — |
Mar 13, 2026 32w ago | Press Release | $0.6290 $0.5500 | ▲ +12.56% | ▲ +16.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers